ArticleEndocrine, metabolic & immune disorders drug targets2026
Mechanism of Gut Microbiota Dysbiosis in Insulin Resistance Polycystic Ovary Syndrome.
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPolycystic Ovary Syndrome (PCOS) is a complex endocrine disorder associated with insulin resistance, hyperandrogenism, and infertility. Gut microbiota dysbiosis is suspected to play a significant role in the pathogenesis of PCOS through the gut-brain-gonad axis, an axis that remains incompletely understood.
methodsThis study aims to evaluate the role of gut microbiota dysbiosis in the mechanism of PCOS with insulin resistance by analyzing the abundance of
resultsThe results showed decreases in DISCUSSION: The study, utilizing an insulin-resistant Polycystic Ovary Syndrome (PCOS) rat model, established a strong, statistically significant link between gut microbiota dysbiosis and endocrine/ metabolic dysfunction. These were observed through increased levels of key markers: Zonulin (Control: 3.775, Treatment: 5.545), HOMA-IR (Control: 78.3400, Treatment: 140.9760), and IGF-1 (Control: 141.9665, Treatment: 189.5700). The Structural Equation Modeling (SEM) analysis confirmed two primary pathogenic pathways: (1) Gut Microbe/Metabolite Pathway: A reduction in beneficial
conclusionThe dysbiosis mechanism involving gut microbiota in this study's model includes PCOS, Zonulin, HOMA-IR, and IGF-1, as these variables demonstrated statistically significant relationships.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.